11/13
06:51 pm
femy
Femasys Inc. (NASDAQ: FEMY) had its price target lowered by analysts at Chardan Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Femasys Inc. (NASDAQ: FEMY) had its price target lowered by analysts at Chardan Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/12
12:35 pm
femy
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/12
11:02 am
femy
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
10:43 am
femy
Femasys GAAP EPS of -$0.24, revenue of $554.91M [Seeking Alpha]
Medium
Report
Femasys GAAP EPS of -$0.24, revenue of $554.91M [Seeking Alpha]
11/12
08:30 am
femy
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Medium
Report
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
11/7
08:38 am
femy
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
08:30 am
femy
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
Low
Report
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
11/1
08:30 am
femy
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
Medium
Report
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
10/31
08:35 am
femy
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/30
09:00 am
femy
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
Neutral
Report
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
10/10
08:30 am
femy
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Low
Report
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
10/8
08:30 am
femy
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Medium
Report
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
10/2
08:30 am
femy
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
Neutral
Report
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
9/18
08:30 am
femy
Femasys Announces Infertility Clinic Customers from Coast to Coast
Low
Report
Femasys Announces Infertility Clinic Customers from Coast to Coast
9/12
08:11 am
femy
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
9/11
08:30 am
femy
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Medium
Report
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
9/10
12:23 pm
femy
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device [Yahoo! Finance]
Low
Report
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device [Yahoo! Finance]
9/9
01:04 pm
femy
FDA clears FemChec for fallopian tube occlusion testing [Yahoo! Finance]
Low
Report
FDA clears FemChec for fallopian tube occlusion testing [Yahoo! Finance]
9/9
08:30 am
femy
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
Medium
Report
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
9/5
08:30 am
femy
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
Low
Report
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
9/3
11:19 am
femy
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI [Yahoo! Finance]
Low
Report
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI [Yahoo! Finance]
9/3
08:30 am
femy
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
8/30
07:00 am
femy
Femasys secures CE mark certification for FemVue MINI solution [Yahoo! Finance]
Low
Report
Femasys secures CE mark certification for FemVue MINI solution [Yahoo! Finance]
8/29
08:30 am
femy
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
Medium
Report
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
8/27
08:30 am
femy
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
Low
Report
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters